Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Integrase inhibiting peptide and its application in preparing AIDS-treating medicine

A technology for inhibiting peptides and integrases, applied in peptides, antiviral agents, pharmaceutical formulations, etc., can solve problems such as peripheral nerve diseases and neutropenia

Inactive Publication Date: 2007-08-22
ZHEJIANG UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the past, the classic AIDS (AIDS) treatment drugs included: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors; Drug resistance, and long-term use of these three types of drugs will also cause side effects such as anemia, neutropenia, myopathy, peripheral nerve disease, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Integrase inhibiting peptide and its application in preparing AIDS-treating medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Using recombinantly expressed HIV-1 integrase as the target protein, positive phage clones were obtained by screening with phage display technology.

[0018] Phage display technology uses molecular biology techniques to clone a set of synthetic oligonucleotide fragments of a certain length into a specific expression vector, so that the expression product is presented on the surface of the phage in the form of a fusion protein. Since the peptide library contains all possible amino acid sequences of small peptides of this length, each phage surface protein presents one of the peptides, which is convenient for screening; the screened phage can be amplified by bacteria. Infect E. coli with the phage peptide library, and the random oligonucleotide fragments recombined into the phage are replicated in E. coli and expressed in the coat protein of the phage. Then, coat the target protein on the microtiter plate. After mixing the phage peptide library with the target...

Embodiment 2

[0021] Embodiment 2: Competitive inhibition ELISA experiment of synthetic heptapeptide

[0022] Test method: Coat 96-well plate with 100ul / well integrase, overnight at 4°C, block with 5% BSA at 37°C for 2h. TPSHSSR at different concentrations of 0, 16.25, 32.5, 65, 130, 260, and 520 μmol / L; The phages mix and compete with the coated integrase for binding. Calculate the phage binding rate: binding rate%=1-(A 450 -A' 450 ) / A 450 ×100%; where A 450 Absorbance at 450nm wavelength without inhibitor, A' 450 Absorbance at a wavelength of 450 nm after adding the inhibitor.

[0023] Test results: With the increase of the heptapeptide added, the binding rate of the phage gradually decreased, that is, the competitive inhibition rate of the corresponding polypeptide increased. See Figure 1. With the increase of the concentration of the synthesized heptapeptide, the corresponding displayed phage and integrase binding rate decreased. The results indicated that these two peptides had...

Embodiment 3

[0024] Embodiment 3: Synthetic heptapeptide inhibition integrase integration activity experiment

[0025] Test method: First, the plasmid pBluescript SK (+) was digested with Sma I at 30°C overnight, and the product was subjected to 1% agarose gel electrophoresis, and the digested product was recovered by cutting the gel, and dissolved in the coating solution (20mmol / L Tris-HCl pH7.4, 20mmol / L EDTA, 2mol / L NaCl), the final concentration of DNA is 2ug / ml; use it to coat a 96-well plate, 100μl per well for 2h at 37°C, or overnight at 4°C. The donor DNA was annealed to two single-stranded oligonucleotide chains (UV5BR: 5'-Biotin-GTGTGGAAAATCTCTAGCAGT-3', UV5: 5'-ACTGCTAGAGATTTTCCACAC-3') synthesized by Shanghai Sangon Bioengineering Technology Service Co., Ltd. become. VU5BR / VU5 was mixed in TEN buffer (10mmol / L Tris-HCl pH8.0, 1mmol / L EDTA pH8.0, 0.1mol / L NaCl) at a ratio of 1:1.2, heated at 80°C for 3min, and slowly cooled to room temperature. Store in a 4°C refrigerator. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides one kind of integrase inhibiting peptide, which is selected from seven kinds of organic polypeptide compounds, a, b, c, d, e, f and g, with molecular weight of 974.3, 770.8, 822.9, 830.9, 849.0, 789.8 and 788.8 separately, is water soluble, and has amino acids connected through peptide bond and capacity of inhibiting the activity of HIV-1 integrase. The organic polypeptide compound of the present invention can inhibit the activity of HIV-1 integrase, and block the proliferation and life period of virus DNA in host cell, and may be applied in preparing medicine for treating AIDS. The present invention may be also used in the further research of integrase structure, action mechanism and AIDS-treating medicine.

Description

technical field [0001] The invention belongs to organic compounds, and mainly relates to polypeptide organic compounds, especially artificially synthesized polypeptide organic compounds and their application in the preparation of drugs for treating AIDS. technical background [0002] The process of viral DNA integration into host cell chromosomal DNA is an extremely important link in the life cycle of retroviruses, and integrase (IN) plays a key role in this link. In the past, the classic AIDS (AIDS) treatment drugs included: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors; Drug resistance, and long-term use of these three types of drugs will also cause side effects such as anemia, neutropenia, myopathy, and peripheral nerve disease. Therefore, in order to overcome the existing problems in the treatment of AIDS, people began to search for drugs that act on new target molecules, and drugs that inhibit the i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61P31/18
Inventor 詹金彪邹媛黄建松冯微宏
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com